FLNC截短变异携带者左室收缩功能障碍与室性心律失常及终末期心衰的关联
这项多中心队列研究纳入167例FLNC截短变异携带者,并与244例左室射血分数匹配的TTN截短变异携带者对照,中位随访20个月。结果显示17.4%达到主要终点,基线轻中度左室收缩功能障碍者中44%发生心律失常事件,且FLNCtv携带者较TTNtv携带者无恶性室性心律失常生存率更低,提示应考虑对FLNCtv携带者在较高LVEF阈值时进行预防性ICD治疗。
要点
- FLNCtv携带者中17.4%在中位20个月内发生恶性室性心律失常或终末期心衰。
- 基线轻中度左室收缩功能障碍者中44%发生恶性室性心律失常事件。
- LVEF每降低10%和先证者状态是主要终点的独立危险因素。
核心结论
- FLNCtv携带者中恶性室性心律失常发生率高,尤其基线轻中度左室收缩功能障碍者,提示预防性ICD治疗应考虑比现行推荐更高的LVEF阈值。
研究设计与样本
- 这项队列研究招募了167例连续FLNCtv携带者和244例LVEF匹配的TTNtv患者,来自19个欧洲心肌病转诊中心,时间跨度为1990年至2018年。
主要发现
- 中位随访20个月(四分位距7-60个月),167例FLNCtv携带者中29例(17.4%)达到主要终点,包括19例恶性室性心律失常和10例终末期心衰。
- 基线轻中度左室收缩功能障碍(LVEF 36%-49%)者中,8例(44%)发生心律失常事件。
- 多变量分析显示LVEF每降低10%的HR为1.83(95%CI 1.30-2.57;P<.001),先证者状态HR为3.18(95%CI 1.12-9.04;P=.03)。
- FLNCtv携带者中轻中度与重度(LVEF≤35%)左室收缩功能障碍者无恶性室性心律失常生存率无差异(HR 1.29;95%CI 0.45-3.72;P=.64)。
- 基线LVEF受损的FLNCtv携带者(n=69)较244例基线LVEF相似的TTNtv携带者无恶性室性心律失常生存率降低(轻中度:HR 16.41;95%CI 3.45-78.11;P<.001;重度:HR 2.47;95%CI 1.04-5.87;P=.03)。
临床怎么用
- 对FLNCtv携带者应加强心律失常风险监测,尤其关注基线轻中度左室收缩功能障碍者,预防性ICD治疗决策可考虑比现行指南更低的LVEF阈值。
局限性
- 多变量分析因病例删失未纳入心肌纤维化和室性异位搏动。
- 中位随访仅20个月,长期风险未充分评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Truncating variants in the gene encoding filamin C (FLNCtv) are associated with arrhythmogenic and dilated cardiomyopathies with a reportedly high risk of ventricular arrhythmia. OBJECTIVE: To determine the frequency of and risk factors associated with adverse events among FLNCtv carriers compared with individuals carrying TTN truncating variants (TTNtv). DESIGN, SETTING, AND PARTICIPANTS: This cohort study recruited 167 consecutive FLNCtv carriers and a control cohort of 244 patients with TTNtv matched for left ventricular ejection fraction (LVEF) from 19 European cardiomyopathy referral units between 1990 and 2018. Data analyses were conducted between June and October, 2020. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of malignant ventricular arrhythmia (MVA) (sudden cardiac death, aborted sudden cardiac death, appropriate implantable cardioverter-defibrillator shock, and sustained ventricular tachycardia) and end-stage heart failure (heart transplant or mortality associated with end-stage heart failure). The secondary end point comprised MVA events only. RESULTS: In total, 167 patients with FLNCtv were studied (55 probands [33%]; 89 men [53%]; mean [SD] age at baseline evaluation, 43 [18] years). For a median follow-up of 20 months (interquartile range, 7-60 months), 29 patients (17.4%) reached the primary end point (19 patients with MVA and 10 patients with end-stage heart failure). Eight (44%) arrhythmic events occurred among individuals with baseline mild to moderate left ventricular systolic dysfunction (LVSD) (LVEF = 36%-49%). Univariable risk factors associated with the primary end point included proband status, LVEF decrement per 10%, ventricular ectopy (≥500 in 24 hours) and myocardial fibrosis detected on cardiac magnetic resonance imaging. The LVEF decrement (hazard ratio [HR] per 10%, 1.83 [95% CI, 1.30-2.57]; P < .001) and proband status (HR, 3.18 [95% CI, 1.12-9.04]; P = .03) remained independent risk factors on multivariable analysis (excluding myocardial fibrosis and ventricular ectopy owing to case censoring). There was no difference in freedom from MVA between FLNCtv carriers with mild to moderate or severe (LVEF ≤35%) LVSD (HR, 1.29 [95% CI, 0.45-3.72]; P = .64). Carriers of FLNCtv with impaired LVEF at baseline evaluation (n = 69) had reduced freedom from MVA compared with 244 TTNtv carriers with similar baseline LVEF (for mild to moderate LVSD: HR, 16.41 [95% CI, 3.45-78.11]; P < .001; for severe LVSD: HR, 2.47 [95% CI, 1.04-5.87]; P = .03). CONCLUSIONS AND RELEVANCE: The high frequency of MVA among patients with FLNCtv with mild to moderate LVSD suggests that higher LVEF values than those currently recommended should be considered for prophylactic implantable cardioverter-defibrillator therapy in FLNCtv carriers.
引用
- Akhtar MM, Lorenzini M, Pavlou M, et al. Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiol. 2021. PMID: 33978673. doi:10.1001/jamacardio.2021.1106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。